Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MORF-057 plus mirikizumab versus mirikizumab alone in moderately to severely active ulcerative colitis
NL-OMON61018Phase 2Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in autoimmune colitis comparing MORF-057 + mirikizumab with Mirikizumab monotherapy (2 arms). Primary endpoint: Clinical remission at Week 12. Started Jun 2026; status: recruiting.
02
Drugs
LY4268989mirikizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON61018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61018.